Showing 1541-1550 of 1690 results for "".
- Underrepresentation in Epilepsy Genome Studies May Increase Health Disparitieshttps://practicalneurology.com/news/underrepresentation-in-epilepsy-genome-studies-may-increase-health-disparities/2470651/Study results presented at the American Epilepsy Society (AES) 2024 Annual Meeting showed a significant lack of diversity in epilepsy genome-wide association studies (GWAS). Most of the participants in these studies were of European ancestry, with an underrepresentation of participants of East As
- Ingrezza Treatment for Tardive Dyskinesia Improved Functional, Social, Emotional, and Health-Related Quality of Life Measureshttps://practicalneurology.com/news/ingrezza-treatment-for-tardive-dyskinesia-improved-functional-social-emotional-and-health-related-quality-of-life-measures/2470633/Treatment with Ingrezza (valbenazine; Neurocrine Biosciences, San Diego, CA) was associated with improvements in functional, social, emotional, and health-related quality of life measures for people with tardive dyskinesia (TD). The findings of 3 separate analyses of clinical study and survey dat
- Insights into Tardive Dyskinesia and Chorea Treatment with Austedo and Austedo XR Reported at Psych Congress 2024https://practicalneurology.com/news/insights-into-tardive-dyskinesia-and-chorea-treatment-with-austedo-and-austedo-xr-reported-at-psych-congress-2024/2470630/The majority of people with TD or chorea associated with Huntington disease (HD) who were treated with Austedo XR (deutetrabenazine; Teva Neuroscience, Kansas City, MO) reported a reduction in extra movement after treatment and satisfaction with the medication, according to real-world patient exp
- AGED Triad of Vascular Aging Linked to Biomarkers of Alzheimer Diseasehttps://practicalneurology.com/news/aged-triad-of-vascular-aging-linked-to-biomarkers-of-alzheimer-disease/2470625/The AGED triad (apathy, gait disturbances, and executive dysfunction), a vascular aging phenotype associated with mood, mobility, and cognitive impairment, has been linked to biomarkers of Alzheimer disease (AD) according to a study presented at the 17th annual Clinical Trials on Alzheimer’
- Favorable Results for Radiprodil Tx for GRIN Disorders Leads to Launch of Study to Test Treatment in Those with Tuberous Sclerosis or Focal Cortical Dysplasiahttps://practicalneurology.com/news/favorable-results-for-radiprodil-tx-for-grin-disorders-leads-to-launch-of-study-to-test-treatment-in-those-with-tuberous-sclerosis-or-focal-cortical-dysplasia/2470617/Treatment with radiprodil (GRIN Therapeutics, New York, NY), a selective, potent negative allosteric modulator of the N-methyl-D-aspartate receptor subtype SB (NR2B or GluN2B), was well tolerated and associated with a significant reduction in seizure frequency in children with GRIN-related neurod
- New Study Uncovers Novel Link Between Football Players, CTE, and Health Problemshttps://practicalneurology.com/news/new-study-uncovers-novel-link-between-football-players-cte-and-health-problems/2470605/Study results published in JAMA Neurology showed that approximately one-third of living former professional American-style football (ASF) players believe they have chronic traumatic encephalopathy (CTE), and this perception is associated with a higher prevalence of suicidality
- Novel DBS Approach Shows Promise for Long-Term Essential Tremor Controlhttps://practicalneurology.com/news/novel-dbs-approach-shows-promise-for-long-term-essential-tremor-control/2470599/A novel deep brain stimulation (DBS) treatment specifically targeting the dentato-rubro-thalamic tract (DRTt) was associated with statistically significant improvements in tremor control for patients with refractory essential tremor (ET) according to study results presented at the 2024 Internatio
- ANA Announces 2024 Scientific Award Winnershttps://practicalneurology.com/news/ana-announces-2024-scientific-award-winners/2470558/The American Neurological Association (ANA) has announced the recipients of their 2024 scientific awards, which will be presented at the organization’s 149th Annual Meeting in September in Orlando, Florida. The awards are intended to honor leaders in the field who have made contributions to
- GLP-1 Agonist Slows Brain Volume Loss and Cognitive Decline in People with Alzheimer Diseasehttps://practicalneurology.com/news/glp-1-agonist-slows-brain-volume-loss-and-cognitive-decline-in-people-with-alzheimer-disease/2470541/Treatment for people with mild Alzheimer disease (AD) using liraglutide, a glucagon-like peptide 1 (GLP-1) agonist, was associated with slower brain volume loss and cognitive decline vs placebo. The results from a phase 2b clinical trial were presented at the 2024 meeting of the Alzheimer’s
- Promising Results for Novel Sigma-1 Receptor Therapy as Alzheimer Treatmenthttps://practicalneurology.com/news/novel-sigma-1-receptor-therapy-slowed-clinical-progression-in-alzheimer-disease/2470543/Treatment with Anavex2-73 (blarcamesine; Anavex Life Sciences, New York, NY) for people with early Alzheimer disease (AD) was associated with slowed clinical progression in cognitive and functional outcomes. Anavex2-73 is a small-molecule activator of the sigma-1 receptor (SIGMAR1) that is orally